NCT06515002 - A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 4, 2024

Primary Completion Date

October 21, 2027

Study Completion Date

February 10, 2028

Conditions

Cystic Fibrosis

Interventions

GENETIC

BI 3720931

DRUG

Placebo

DEVICE

Inhaler

Inhaler for application of BI 3720931 and placebo

Trial Locations (10)

Istituto G. Gaslini, Genova

HOP Gui de Chauliac, Montpellier

HOP Necker, Paris

Osp. Pediatrico Bambin Gesù, Roma

Universitair Medisch Centrum Utrecht, Utrecht

Hospital Universitari Vall D Hebron, Barcelona

University Hospital Llandough, Cardiff

Queen Elizabeth University Hospital, Glasgow

Royal Brompton Hospital, London

Wythenshawe Hospital, Manchester